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The newly described human metapneumovirus (hMPV) is reported here to be more commonly associated
with lower respiratory tract disease. The present study examined nasal swab specimens from 90 infants with
acute respiratory tract infections in Pisa, Italy, over a period of three respiratory virus seasons. The incidence
of infection varied in each of the 3 years, with the rates of positivity for hMPV being 7% in 2001 but 37 and 43%
in 2000 and 2002, respectively. hMPV was noted to occur seasonally in a pattern typical of the frequency of
occurrence of respiratory syncytial virus. More than one-half (14 of 23) of the infants infected with hMPV had
bronchopneumonia. One-third (9 of 23) of the hMPV-infected patients were also infected with another
respiratory virus, a relationship that has not previously been reported. Mixed infections did not account for a
higher percentage of cases of bronchopneumonia than hMPV infection alone did. Furthermore, 7 of 17 infants
whose plasma was also tested for hMPV RNA were demonstrated to have virus in both nasal swab and blood
specimens. The study indicates that hMPV is seen as commonly as other respiratory viruses, may be associated
with severe respiratory disease in infants, can establish mixed infections with other respiratory viruses, and
has a seasonal occurrence.
A newly identified virus capable of causing acute human
respiratory disease has been reported (12) and demonstrated
to be present mostly in children in Europe, North America,
and Australia (2, 7, 9), suggesting a worldwide distribution.
The name human metapneumovirus (hMPV) has been sug-
gested for this paramyxovirus but awaits formal classification
by the International Committee on the Taxonomy of Viruses.
This would place the virus in the genus metapneumovirus,
which previously included only avian metapneumoviruses (3).
Metapneumoviruses are pleomorphic, enveloped virions with
an average diameter of approximately 200 nm (range, 150 to
1,000 nm), contain single-stranded RNA of negative polarity
that forms a helical nucleocapsid, and have surface glycopro-
teins and projections (3, 9, 12, 13). Filamentous rod-like par-
ticles have also been seen by electron microscopy (12). The
virus is not able to agglutinate red blood cells (12). Sequence
analysis of the RNA of isolates of the virus has revealed that it
is most closely related to avian metapneumovirus subtype C
and is more closely related to all avian metapneumoviruses
than to other paramyxoviruses, including the human respira-
tory pathogens parainfluenza viruses and human respiratory
syncytial virus (hRSV) (13). Both serologic and molecular
analyses have shown that the virus is unique compared to all
other known human respiratory pathogens.
In retrospective studies the virus has been detected in nu-
merous respiratory specimens from individuals with respira-
tory infections for which an etiologic agent was not initially
detected. The reason for the difficulty in isolating this virus is
that it does not grow readily in tissue culture cells routinely
used in the viral diagnostic laboratory and grows only slowly in
tertiary monkey kidney cells (12). In the few studies reported
to date, it appears that less than 10% of respiratory infections
for which no causative agent was previously identified may
have been due to hMPV (7). van den Hoogen and colleagues
(12) report that 100% of individuals 5 to 10 years of age or
older who were tested serologically showed antibodies and that
by age 2 years 55% were positive. Despite the evidence of
antibodies in every adult tested, the virus was isolated from
some adults with acute respiratory disease, suggesting that
repeated infections may occur, as is seen with hRSV (1, 9).
Molecular tools have been developed so that the virus can be
detected by PCR as well as serologically (9, 12, 13). A sero-
survey of specimens collected in 1958 showed that the virus has
circulated in The Netherlands for at least 44 years, but no
studies have examined older sera (12).
Sequence analysis has demonstrated that there are two ma-
jor groups or lineages of hMPV and that sequence diversity
exists within the groups (13). Specimens from one child that
were collected in consecutive years demonstrated that the child
had been infected with hMPV isolates of the two different
subgroups each year, indicating that an individual may be in-
fected with a virus from one subgroup and not be protected by
a previous infection with virus of the other subgroup (8).
Clinical disease associated with hMPV appears to be similar
to that associated with hRSV, ranging from mild upper respi-
ratory tract infection to bronchiolitis and bronchopneumonia
(1, 4, 7, 9, 11, 12). Studies with juvenile birds and monkeys
suggest that the virus replicates and can cause respiratory
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symptoms of infection in the primates but not in the avian
species (12). In that study no virus was detected in the monkeys
at 24 h postinfection, but virus titers peaked between 2 and 8
days postinfection (12). Additionally, in that study ferrets and
guinea pigs were inoculated with virus to generate antibodies,
but the animals exhibited no evidence of clinical infection.
In the present study, the diagnostic virology laboratory at the
University of Pisa examined 90 nasal swab specimens from
infants (age, less than 2 years) routinely submitted for the
examination of respiratory tract infections. This study indi-
cated that hMPV was present in our patient population and
that the incidence varied in each of the 3 years tested.
MATERIALS AND METHODS
Patients, sample collection, and routine tests. Simultaneous nasal and plasma
specimens were harvested on the day of admission, following the receipt of
informed parental consent, from 90 children with acute respiratory diseases (42
children with bronchopneumonia, 48 children with milder forms of acute respi-
ratory disease) admitted to the Department of Pediatrics, University Hospital of
Pisa. All children were negative for hepatitis B virus surface antigen and hepatitis
C virus and human immunodeficiency virus antibodies, and none had received
antiviral drugs. The nasal secretions of these children were quantified by weigh-
ing the swabs before and after collection and were then diluted 1:10 (wt/vol) with
phosphate-buffered saline and clarified by centrifugation at 900  g at 4°C for 10
min to separate the cells and cell debris. Finally, the cell-free nasal fluid was
stored in aliquots at 20°C until RNA extraction. All nasal swab samples were
tested for common respiratory viruses by direct immunofluorescence (adenovi-
rus, cytomegalovirus, influenza A and B viruses, parainfluenza viruses types 1 to
3, hRSV), enzyme immunoassay (hRSV), and rapid culture in shell vials (all
viruses mentioned above). Plasma was obtained by spinning down blood col-
lected under nuclease-free conditions in tubes containing sodium citrate.
hMPV PCR. A 170-bp segment of the L gene spanning nucleotides 11321 to
11490 of hMPV prototype strain 00-1 was amplified by using a single-step reverse
transcription (RT)-PCR. Briefly, viral RNA was extracted with the QIAmp Viral
RNA kit (QIAgen, Chatsworth, Calif.) and amplified with the OneStep RT-PCR
kit (QIAgen) with antisense primer L7 (5-CACCCCAGTCTTTCTTGAAA-3;
positions 11471 to 11490) and sense primer L6 (5-CATGCCCACTATAAAA
GGTCAG-3; positions 11321 to 11342) under the following conditions: reverse
transcription at 50°C for 30 min; an initial PCR activation step at 95°C for 15
min; and 40 subsequent PCR cycles with melting at 94°C for 30 s, annealing at
55°C for 30 s, and extension at 72°C for 60 s. The reactions were carried out in
a 50-l format by using a PCR Master Mix containing RT-PCR enzyme mix
(Omniscript and Sensiscript reverse transcriptases and HotStartTaq DNA poly-
merase), each deoxynuceloside triphosphate at a concentration of 400 M,
primers (0.9 M each), and optimized buffer components. Finally, the amplified
product was analyzed by electrophoresis on an agarose gel after ethidium bro-
mide staining, and the sizes of the amplicons were compared with standard
molecular size markers. To validate the amplification process and to exclude the
presence of carryover contamination, positive and negative controls were run in
each PCR. All samples were tested at least in duplicate, and those found to be
positive were tested again starting from an independent RNA extraction. The
sensitivity of the assay was measured by testing serial dilutions of a known
concentration of RNA transcribed from a recombinant plasmid into which the
target fragment of the L gene of hMPV was inserted and was found to be less
than 10 RNA copies. Specificity was demonstrated by sequencing a large number
of the amplification products.
Sequencing. The region sequenced was a 128-bp segment (nucleotides 11343
to 11470) obtained by subtracting the primer nucleotides from the 170-bp am-
plicon. Sequencing was carried out in both orientations by using the Big Dye
Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, Calif.) and
an automatic DNA sequencer (ABI model 310; Applied Biosystems). The nu-
cleotide sequences were aligned with previously published sequences. Multiple-
sequence alignments were performed by the CLUSTALW method with a 102-bp
segment known to be valuable for hMPV genotyping (9, 12) and for which a large
number of sequences exist in GenBank.
Nucleotide sequence accession numbers. All sequences obtained in this study
have been deposited in GenBank and have been given accession numbers
AY168973 to AY168987.
RESULTS
Evidence of hMPV infections. The patients recruited for this
study comprised 90 children (60 males, 30 females; age range,
1 to 24 months; mean age, 7.8 5.5 months) hospitalized from
January 2000 to May 2002. Nasal swabs from these children
were tested for hMPV by PCR with a primer set specific for the
L protein (polymerase) which detects both genotypes of the
virus (5, 9, 12), and 23 nasal swabs yielded positive results
(Table 1). The rate of positivity held rather steady at about
25% when the subjects were divided into three age groups,
although the youngest patients had the highest rate of positiv-
ity.
Interestingly, of 28 specimens in which hRSV or other vi-
ruses were detected in infants, 9 were positive for hMPV and
another virus and 2 specimens yielded a mixed infection with
three viruses. Twenty-one of 75 (28%) samples from patients
who exhibited lower respiratory tract infections (bronchiolitis
or pneumonia) were hMPV positive, and 2 of 15 (13%) sam-
ples from patients with only upper respiratory tract infections
were hMPV positive.
hMPV and association with disease severity. Nasal swabs
from 42 infants were found to be positive for one or more
viruses (Table 2). Twenty-three of these infants were demon-
strated to have hMPV in their nares, and 14 (61%) of these
developed bronchopneumonia, while those infected with other
viruses had a bronchopneumonia rate of only 16% (3 of 19
infants). The rate of bronchopneumonia was not altered by the
presence of a second virus in infants with hMPV. Thus, the
majority of patients demonstrating hMPV in nasal swabs de-
veloped pneumonia, while lung involvement was noted in a
smaller proportion of patients infected with other viruses.
When the plasma of 17 individuals whose nasal swabs were
positive for hMPV was subsequently tested for viral RNA, the
TABLE 1. hMPV RNA detection in nasal swabs from 90 infants
with acute respiratory diseases
Parameter No. of infantsexamined
No. (%) of infants
hMPV RNA positive
Age (mo)
3 11 4 (36)
4–12 44 12 (27)
13–24 35 7 (20)
Common respiratory viruses
Negative 62 14 (23)
Positive
hRSV alone 20 4 (20)
Othersa 8 5b,c (62)
Clinical diagnosis
Bronchopneumonia 42 14 (33)
Bronchiolitis 33 7 (21)
Bronchitis 8 1 (12)
Laryngitis 7 1 (14)
Total 90 23 (25)
a Including cytomegalovirus (n  3), adenovirus (n  3), influenza A virus (n
 1), and parainfluenza virus type 3 (n  1).
b Another virus, one adenovirus and one parainfluenza virus type 3, was also
present in two nasal fluid specimens positive for hRSV.
c Significantly different from the results for specimens with hRSV alone and
negative specimens at P  0.03 and P  0.017, respectively (chi-square test).
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plasma of 7 was found to be positive (Table 2). Of these seven
individuals, 5 had bronchopneumonia and 2 had milder acute
respiratory disease.
hMPV and seasonal distribution. The specimens studied
were collected mainly during the respiratory disease seasons of
three calendar years, 2000, 2001, and 2002 (Table 3). There
was a distinct difference in the number of hMPV-positive spec-
imens in 2001 compared with the numbers in the other two
years, with the numbers of hMPV-positive specimens in 2000
and 2002 being essentially identical. The data for hMPV are
consistent with the findings for all viruses isolated from 171
nasal swab specimens in the same patient population; rates of
isolation in 2001 were lower for all respiratory viruses. Testing
for hMPV was not performed with the specimens from patients
older than age 2 years. However, the decrease in the rate of
hMPV detection was statistically significant compared to the
rate of detection in the other years, similar to the observation
for other respiratory viruses. While a decrease in the number
of hMPV-positive specimens was also noted for hRSV in 2001
compared to the numbers in the other years, it was not statis-
tically significant.
The seasonal distribution of infection across the 3 years is
consistent with the expected incidence, as 21 of 67 (31%)
specimens submitted between January and May were hMPV
positive, while only 2 of 23 specimens (9%) submitted between
June and December were hMPV positive (Table 4). Both of
these hMPV-positive samples submitted later in the year were
detected in the fall of 2000, one in October and one in De-
cember.
Genetic analysis of hMPV isolates. Sequencing was limited
to 15 amplicons from independent PCR runs because this
number was considered an appropriate sampling of the total of
23 amplicons obtained. Phylogenetic analysis showed that all
but one of the isolates sequenced (isolate 121-02) were in the
same hMPV group (Fig. 1). Most of the strains were very
closely related, and the sequence analyzed was virtually iden-
tical for a few strains. When nasal swab and blood specimens
from the same patient were analyzed phylogenetically, some
small changes were noted in the isolates from three of five
patients, but the viruses in both types of samples were identical
in two patients (data not shown). Of interest, clustering of the
isolates was independent of the patient’s age or disease.
DISCUSSION
The recent discovery of hMPV, a new virus associated etio-
logically with acute human respiratory tract infections in Eu-
rope, North America, and Australia, inspired an investigation
of nasal swab specimens collected from infants in Pisa, Italy (2,
7, 9, 12). This investigation confirmed that hMPV can be as-
sociated with clinical disease and extends the previous findings.
Previous studies had been limited to patients who had respi-
ratory infections for which no etiology had been detected. In
the present study, nasal swab specimens were taken from chil-
dren less than 2 years old with respiratory infections and were
tested for the presence of hMPV as well as other respiratory
viruses. Among the hMPV-positive specimens, more were iso-
lated from infants with bronchpneumonia (14 of 23) than from
infants with milder acute respiratory disease (9 of 23). This is
consistent with recent reports showing a higher prevalence of
hMPV in children with lower respiratory tract infections than
in children with upper respiratory tract infections (1, 7). The
other studies that identified hMPV in clinical specimens did
not provide information on the severity of disease (9, 12). Even
TABLE 2. Prevalence of hMPV and/or other respiratory viruses
in the 42 infants found to be virus positive and grouped by
clinical diagnosis
Virus No. of infantstested





hMPV alone 14 9b (64) 5c (36)
hMPV and other RVd 9 5e (56) 4f (44)
Other RV alone 19 3 (16)g 16 (84)
a ARD, acute respiratory diseases, including bronchiolitis, bronchitis, and lar-
yngitis.
b The plasma of four of eight patients whose plasma was tested was positive.
c The plasma of one of four patients whose plasma was tested was hMPV
positive.
d RV, respiratory viruses.
e The plasma of one of three patients whose plasma was tested was hMPV
positive.
f The plasma of one of two patients whose plasma was tested was hMPV
positive.
g Significantly different from the results for patients positive for bronchopneu-
monia caused by hMPV alone and positive for bronchopneumonia caused by
hMPV and respiratory viruses at P 0.004 and P 0.03, respectively (chi-square
test).
TABLE 3. Prevalence of hMPV and other respiratory viruses in
















2000 19 7 (37) 80 44 (55) 29 (36)
2001 41 3 (7)c 59 22 (37)d 16 (27)
2002 30 13 (43) 32 18 (56) 15 (47)
a RV, respiratory viruses, including hRSV, cytomegalovirus, adenovirus, influ-
enza A virus, and parainfluenza viruses types 1 to 3.
b Included in the total specimens examined for other respiratory viruses in
each year.
c Significantly different from the results for hMPV-positive samples in the
years 2000 and 2002 at P  0.004 and P  0.0003, respectively (chi-square test).
d Significantly different from the results for other respiratory virus-positive
samples in the year 2000 at P  0.038 (chi-square test).















2000 10 5 (50) 9 2 (22)a
2001 27 3 (11) 14 0 (0)
2002 30 13 (43) NAb NA
Total 67 21 (31) 23 2 (9)
a One sample was positive in October, and one sample was positive in De-
cember.
b NA, not available.
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more interesting was the finding that many more cases of
bronchopneumonia were associated with hMPV infection than
infection with the other viruses (only three cases) in the ab-
sence of hMPV. It must be noted that 5 of 17 cases of bron-
chopneumonia were mixed infections with hMPV and other
viruses, but the rate of bronchopneumonia in those infected
with hMPV alone (64%) was as high as the rate of broncho-
pneumonia in those with mixed infections with hMPV and
another virus (56%). In this regard, it should also be noted that
the mixed infections recognized would most likely have been
more numerous if the detection methods used for common
respiratory viruses were as sensitive as the PCR assay used for
hMPV detection. Thus, mixed infections do not necessarily
result in more severe infection, but detection of hMPV may be
a predictor of potentially more serious disease in infants. Since
the previous studies did not examine specimens for hMPV if
they were known to contain another virus, there is no indica-
tion of whether the rate of mixed infection in the Pisa patients
is typical or unusual. Taken together, the present findings
suggest that hMPV might be associated with a high rate of
serious respiratory infections in hospitalized infants; however,
because the number of infants studied was small, the issue
clearly needs further investigation.
Earlier studies, based on the presence of anti-hMPV anti-
bodies, indicate that by age 2 years the proportion of children
with evidence of previous hMPV infection is approximately
55% and that by age 5 to 10 years the proportion is 100% (12).
The detection of anti-hMPV antibodies in 100% of older chil-
dren suggests that most infections are not associated with se-
rious disease, yet data are lacking on the proportion of infec-
tions that are associated with serious disease. While the
incidence in the Australian study was only 1.5%, all were as-
sociated with lower respiratory tract disease (7). In the present
study, a high proportion (25%) of the infants less than 2 years
old who required hospitalization for acute respiratory disease
were hMPV positive, and most of these (21 of 23) had lower
respiratory tract involvement. The incidence noted was some-
what higher than that noted in the studies reported previously,
but the range of clinical disease was similar (2, 7, 9, 11, 12).
This difference in incidence is likely related to the difference in
the patient populations studied, as the other studies did not
indicate that samples were limited to those from children less
than 2 years old. It is probable that most hMPV infections are
mild or subclinical in all age groups but that the ones that occur
before age 2 may be associated with more severe disease.
Another interesting observation is that hMPV RNA was
demonstrated in the plasma of 41% of patients in whom hMPV
was detected in their nasal passages. This finding, although
surprising, is consistent with a report on hRSV which showed
that the majority of patients who had virus in their nasal wash-
ings had viral RNA in their blood (10). In that study, both types
of specimens from 14 of 41 patients were positive, while the
nasal washings were virus positive and the blood was negative
for only 5 patients. It is unclear at present what the significance
of finding hMPV in plasma implies regarding clinical disease;
however, among the patients in whom virus was demonstrated
in their blood, a higher percentage had serious disease. These
studies must be expanded before any definitive information
can be derived.
As a result of studying specimens over the course of three
respiratory infection seasons, we noted a pattern in which the
incidence of hMPV in this population was not consistent for
the 3 years. Approximately 40% of the samples yielded hMPV
RNA in 2000 and 2002, yet only 7% were positive in 2001.
While this pattern of alternating years of high and low inci-
dence is consistent with what is observed for other respiratory
viruses, it is not clear if this was coincidence or a real pattern.
Furthermore, when we examined the overall pattern of inci-
dence of respiratory tract infections, we saw that the pattern
for hMPV was similar to those for other respiratory viruses and
hRSV, as the overall rate of positive specimens was lower in
FIG. 1. Phylogenetic analysis of 15 hMPV isolates from the present
study. The tree is based on a 102-bp segment from the L gene of the
viral genome. The branching pattern of the tree was obtained by the
neighbor-joining algorithm, with randomization of the input order of
sequences. Bootstrap resampling was used to test the robustness of the
tree, and bootstrap values above 90% for 1,000 replicates are shown at
the branch points. Genetic distances were calculated by using the
Poisson correction distance (Poisson P), as provided by the DAMBE
program (version 4.1.0). Nasal isolates from the present study are
shown in boldface and are labeled with the year of specimen collection
(last two digits). GenBank sequences are indicated by isolate name.
Avian pneumovirus C (APV-C; GenBank accession number
AF176591) was used as the outgroup. The bar represents the number
of nucleotide substitutions per site.
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2001. The seasonal incidence was as expected for respiratory
tract infections, with 91% of hMPV-positive samples being
collected from January to May, paralleling what is normally
seen in Pisa for hRSV (6). The positive two specimens that
were collected in the fall of 2000 may indicate the early onset
of the respiratory virus season that year, which is also consis-
tent with what is reported for hRSV in some years (6). Thus,
while there is a suggestion of a cyclic pattern of occurrence of
hMPV, analysis of more data from future respiratory virus
seasons will need to be evaluated to establish a true pattern.
Molecular analysis of the hMPV RNA of the isolates from
several of these patients indicated that the virus seen in Pisa is
similar to those identified in The Netherlands and North
America (9, 12). Most sequences clustered into one lineage,
while one sequence was in a second cluster (Fig. 1). Previous
reports indicate that there are two hMPV subgroups (9, 12,
13). This study of specimens submitted to the diagnostic virol-
ogy laboratory in Pisa raises a number of provocative points
based on the data collected. The incidence of infection in Pisa
appears to be considerably higher than that reported in the
first reports concerning this new respiratory virus, although
none of those studies looked at all nasal wash specimens sub-
mitted; rather, they examined only those specimens found to
be negative for other viruses. Despite the data collected in the
present study, the only confirmed association of hMPV with
disease causation is in an experiment with cynomolgus mon-
keys (12). Thus, criteria must be fulfilled to demonstrate de-
finitively that hMPV is a cause of respiratory infection in hu-
mans. A concerted effort to study the incidence of hMPV in
numerous locales is certainly warranted if the association with
severe lower respiratory tract infection is to be seriously con-
sidered.
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